ReviewJournal of the International Association of Providers of AIDS Care
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.
Review in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Global prevalence of chronic kidney disease and its influencing factors among chronic hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.Clinical pharmacokinetics · 2023Pooled it
- Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis.Jornal brasileiro de nefrologiaPooled it
- A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.Hepatology (Baltimore, Md.) · 2026Trial
- Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial.AIDS and behavior · 2025Trial
- Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.The Journal of antimicrobial chemotherapy · 2024Trial
- HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo.The Journal of infectious diseases · 2024Trial
- Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023Trial
- Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.Frontiers in endocrinology · 2023Trial
- Cytogenetic changes in oral mucosal cells of human immunodeficiency virus-infected children and adolescents undergoing antiretroviral treatment.Revista da Associacao Medica Brasileira (1992) · 2023Trial
- Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.AIDS (London, England) · 2021Trial
- Beyond Viral Control: Tenofovir's Hidden Impact on Blood-Brain Barrier Endothelial Cells.Microcirculation (New York, N.Y. : 1994) · 2026Article
- Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches.Current microbiology · 2026Review
- How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19.Clinical and translational science · 2026Review
- Prodrug strategies in developing antiviral nucleoside analogs.RSC medicinal chemistry · 2026Review
- Tenofovir-Associated Hypophosphatemic Osteomalacia in an HIV-Infected Patient: A Case Report.Cureus · 2026Article
- Xanthine oxidase inhibition by medicinal plants mitigates tenofovir-induced nephrotoxicity: a comprehensive computational and experimental study.Frontiers in pharmacology · 2026Article
- The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.Le infezioni in medicina · 2026Review
- The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review.Biochemistry and biophysics reports · 2025Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications. Some of the older agents are notorious for many side effects, making patient compliance difficult, which is critical to preventing HIV resistance. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral therapy combinations; and is now available in 2 different formulations, tenofovir disoproxil fumarate (TDF) and, the more recent, tenofovir alafenamide (TAF). These 2 formulations have very different pharmacokinetics, which seem to affect their efficacy and safety. This manuscript provides insight into the history of TDF and TAF development, their unique pharmacokinetics and pharmacology, clinically important adverse effects, monitoring, interactions, resistance, review of clinical studies, and guideline recommendations and clinical applications for tenofovir's various indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.